1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-...1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2016,17(6):822-835.2证据水平1b。3背景?在完全切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,只有不到一半的患者被治愈,而其他患者的癌症复发通常是致命的。在过去的几十年里,已研究了几种辅助治疗方法来改善这些患者的预后。?目前发现MAGE-A3是肿瘤组织表达最多的肿瘤-睾丸抗原(cancer-testis antigen,CTA)之一,被认为是真正的肿瘤特异性抗原,在许多肿瘤中表达,例如恶性黑色素瘤、肺癌、头颈部肿瘤、肝细胞癌等。30%~50%的NSCLC存在MAGE-A3表达,其中鳞癌(48%)比非鳞癌(24%)比例更高。而对于可切除的NSCLC,只有不到一半的患者达到临床治愈,更多的患者会出现肿瘤复发。传统的辅助化疗无法提供更多的临床获益,针对MAGE-A3抗原的肺癌疫苗对术后患者体内残存的癌细胞可能具有一定的治疗潜力。展开更多
1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Cli...1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Clin Oncol,2020,38(21):2369-2379.2证据水平1b。3背景依托泊苷联合铂类是广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)一线标准治疗方案之一。帕博丽珠单抗单药在小细胞肺癌中显示出抗肿瘤活性。展开更多
1文献来源研究一:Rudin CM,Poirier JT,Byers LA,et al.Molecular subtypes of small cell lung cancer:A synthesis of human and mouse model data[J].Nat Rev Cancer,2019,19(5):289-297.研究二:Owonikoko TK,Dwivedi B,Chen ZJ,et a...1文献来源研究一:Rudin CM,Poirier JT,Byers LA,et al.Molecular subtypes of small cell lung cancer:A synthesis of human and mouse model data[J].Nat Rev Cancer,2019,19(5):289-297.研究二:Owonikoko TK,Dwivedi B,Chen ZJ,et al.YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival[J].J Clin Oncol,2020,38(15S):Abstr 9019.展开更多
1文献来源Yang JJ,Zhou CC,Huang YS,et al.Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases(BRAIN):A multicentre,phase 3,open-label,parallel,ra...1文献来源Yang JJ,Zhou CC,Huang YS,et al.Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases(BRAIN):A multicentre,phase 3,open-label,parallel,randomised controlled trial[J].Lancet Respir Med,2017,5(9):707-716.2证据水平1b。3背景-目前全脑放疗(whole-brain radiation therapy,WBRT)仍是非小细胞肺癌(non-small cell lung cancer,NSCLC)多发性脑转移的标准治疗方式,而对于EGFR突变的患者,第一代和第二代TKI不仅显著提高了无进展生存期,而且对脑转移有一定的疗效。展开更多
1文献来源Pezzi TA,Mohamed ASR,Fuller CD,et al.Radiation therapy is independently associated with worse survival after R0-resection for stageⅠ~Ⅱnon-small cell lung cancer:An analysis of the National Cancer Data Base[...1文献来源Pezzi TA,Mohamed ASR,Fuller CD,et al.Radiation therapy is independently associated with worse survival after R0-resection for stageⅠ~Ⅱnon-small cell lung cancer:An analysis of the National Cancer Data Base[J].Ann Surg Oncol,2017,24(5):1419-1427.2证据水平2a。3背景1998年发表的一篇针对肺癌术后放射治疗的荟萃分析显示,Ⅰ~Ⅱ期手术切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受术后放射治疗(postoperative radiotherapy,PORT)与更差的生存预后相关,但考虑与当时落后的放疗仪器及技术也有一定关系。已有利用美国国家癌症数据库(National Cancer Data Base,NCDB)的真实世界研究发现pN2的NSCLC患者行PORT能够获得生存获益,因此,本文旨在运用该数据库分析早期(Ⅰ~Ⅱ期)NSCLC行PORT获益情况。随着放疗仪器及技术改进后,R0切除的Ⅰ~Ⅱ期NSCLC行PORT与预后关系尚未可知。展开更多
1文献来源Chabon JJ,Hamilton EG,Kurtz DM,et al.Integrating genomic features for non-invasive early lung cancer detection[J].Nature,2020,580(7802):245-251.2证据水平1b。3背景低剂量螺旋CT是目前肺癌早筛的主要方法,但是其较...1文献来源Chabon JJ,Hamilton EG,Kurtz DM,et al.Integrating genomic features for non-invasive early lung cancer detection[J].Nature,2020,580(7802):245-251.2证据水平1b。3背景低剂量螺旋CT是目前肺癌早筛的主要方法,但是其较高的假阳性率和较低的依从性仍然限制了它的应用率。展开更多
1文献来源Camidge DR, Kim HR, Ahn MJ, et al.Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer[J]. N Engl J Med,2018,379(21):2027-2039.
文摘1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2016,17(6):822-835.2证据水平1b。3背景?在完全切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,只有不到一半的患者被治愈,而其他患者的癌症复发通常是致命的。在过去的几十年里,已研究了几种辅助治疗方法来改善这些患者的预后。?目前发现MAGE-A3是肿瘤组织表达最多的肿瘤-睾丸抗原(cancer-testis antigen,CTA)之一,被认为是真正的肿瘤特异性抗原,在许多肿瘤中表达,例如恶性黑色素瘤、肺癌、头颈部肿瘤、肝细胞癌等。30%~50%的NSCLC存在MAGE-A3表达,其中鳞癌(48%)比非鳞癌(24%)比例更高。而对于可切除的NSCLC,只有不到一半的患者达到临床治愈,更多的患者会出现肿瘤复发。传统的辅助化疗无法提供更多的临床获益,针对MAGE-A3抗原的肺癌疫苗对术后患者体内残存的癌细胞可能具有一定的治疗潜力。
文摘1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Clin Oncol,2020,38(21):2369-2379.2证据水平1b。3背景依托泊苷联合铂类是广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)一线标准治疗方案之一。帕博丽珠单抗单药在小细胞肺癌中显示出抗肿瘤活性。
文摘1文献来源研究一:Rudin CM,Poirier JT,Byers LA,et al.Molecular subtypes of small cell lung cancer:A synthesis of human and mouse model data[J].Nat Rev Cancer,2019,19(5):289-297.研究二:Owonikoko TK,Dwivedi B,Chen ZJ,et al.YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival[J].J Clin Oncol,2020,38(15S):Abstr 9019.
文摘1文献来源Pezzi TA,Mohamed ASR,Fuller CD,et al.Radiation therapy is independently associated with worse survival after R0-resection for stageⅠ~Ⅱnon-small cell lung cancer:An analysis of the National Cancer Data Base[J].Ann Surg Oncol,2017,24(5):1419-1427.2证据水平2a。3背景1998年发表的一篇针对肺癌术后放射治疗的荟萃分析显示,Ⅰ~Ⅱ期手术切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受术后放射治疗(postoperative radiotherapy,PORT)与更差的生存预后相关,但考虑与当时落后的放疗仪器及技术也有一定关系。已有利用美国国家癌症数据库(National Cancer Data Base,NCDB)的真实世界研究发现pN2的NSCLC患者行PORT能够获得生存获益,因此,本文旨在运用该数据库分析早期(Ⅰ~Ⅱ期)NSCLC行PORT获益情况。随着放疗仪器及技术改进后,R0切除的Ⅰ~Ⅱ期NSCLC行PORT与预后关系尚未可知。
文摘1文献来源Chabon JJ,Hamilton EG,Kurtz DM,et al.Integrating genomic features for non-invasive early lung cancer detection[J].Nature,2020,580(7802):245-251.2证据水平1b。3背景低剂量螺旋CT是目前肺癌早筛的主要方法,但是其较高的假阳性率和较低的依从性仍然限制了它的应用率。
文摘1文献来源Camidge DR, Kim HR, Ahn MJ, et al.Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer[J]. N Engl J Med,2018,379(21):2027-2039.
